VisEn Medical expands FMT imaging platform

Apr 16 2010NewsGuard 100/100 Score

VisEn Medical Inc., a leader in fluorescence imaging solutions from research through medicine, announced today that it has expanded its leading FMT imaging platform with an FMT™ Multi-Species Imaging Module, to extend FMT imaging and related applications into larger preclinical animal models.  VisEn also announced that it will be presenting new study results from its recently-launched Cat B 750 FAST™ and Annexin-Vivo™ fluorescence imaging agents at the AACR (American Association of Cancer Research) 101st Annual Meeting, highlighting translational imaging advances in leading oncology research.  The AACR Annual Meeting is being held in Washington, DC from April 17 – 21, 2010.

Source:

VisEn Medical Inc.

Posted in: Drug Trial News | Device / Technology News | Medical Condition News

Tags: , , , , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Are back problems influenced by your gut?
Brain aging may hold the key to predicting Alzheimer’s risk
Understanding cardiovascular risks in endometriosis patients
Mapping tumor microenvironments: Uncovering spatial subclones for improved cancer treatment
Scientists reveal how miRNAs shape cancer and offer new paths for treatment
Mild COVID-19 disrupts brain connectivity and reduces memory function in adolescents and young adults
Study finds prenatal sleep quality affects newborn brain structure and emotional health
New 3D body scan method beats traditional imaging for tracking body fat

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Bruker Introduces Innovative Neuroscience Research Solution with High-Speed OptoVolt Voltage Imaging